Boryung said on Thursday it signed a contract development and manufacturing organization (CDMO) agreement with Lotus Pharmaceutical, a Taiwanese oncology specialist, for the production of a cytotoxic agent.
Under the agreement, Boryung will manufacture an anticancer injection for Lotus. Boryung plans to supply the agent to Lotus starting in 2026, Boryung said. The latest agreement demonstrates Boryung's manufacturing capabilities for strategic essential drugs, building on its existing manufacturing and distribution capacity in Korea, it added.
Boryung's CDMO deal with Lotus Pharmaceutical marks its first step into the global CDMO business.
Boryung's EU-GMP certified plant in Yesan, South Chungcheong Province (Courtesy of Boryung)
Boryung's EU-GMP certified plant in Yesan, South Chungcheong Province (Courtesy of Boryung)
By acquiring and producing strategic original essential medicines for overseas markets, Boryung aims to accelerate its strategic growth.
Boryung will manufacture the anticancer drug at its EU-GMP-certified factory in Yesan, South Chungcheong Province. The facility, designed by Novo Nordisk Engineering (NNE), has a capacity to produce 6 million vials per year. The facility's Intermediate Bulk Container (IBC) BIN system automates the entire process from raw material weighing to packaging, eliminating the risk of contamination and cross-contamination.
Boryung aims to expand its global market reach by obtaining EU-GMP certification for oral drugs in 2025, adding to its existing certification for cytotoxic anticancer injectables.
"This CDMO contract confirms Boryung's globally recognized manufacturing capabilities and reliability," said Kim Sung-jin, Chief Strategy Officer of Boryung. “We will further reinforce our differentiated CDMO business by manufacturing and globally supplying original essential drugs."
Since 2020, Boryung has acquired key original drugs based on the Legacy Brands Acquisition (LBA) strategy.
The company acquired the domestic rights to the anticancer drug Gemzar (gemcitabine) in 2020, the schizophrenia drug Zyprexa (olanzapine) in 2021, and the non-small cell lung cancer drug Alimta (pemetrexed) in 2022 from Lilly.
Related articles
Boryung pledges stable supply of essential anticancer drugs following price adjustment
Boryung eyes ₩1 tril. annual sales after record-breaking H1 earnings
Boryung and Bixink to co-market Nerlynx for HER2-positive breast cancer
How could Boryung triple its anticancer drug business in 4 years?
Kim Yoon-mi yoonmi@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited